Apriso (Ulcerative Colitis) - Forecast and Market Analysis to 2022


Naperville, IL -- (SBWIRE) -- 04/30/2014 -- Reportstack, provider of premium market research reports announces the addition of Apriso (Ulcerative Colitis) - Forecast and Market Analysis to 2022 market report to its offering
Apriso (Ulcerative Colitis) - Forecast and Market Analysis to 2022


During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

Apriso features an Intellicor-coated gel suspension of mesalamine. The Intellicor coating that enables the release of mesalamine exclusively in the colon, dissolving at pH =6. Therefore, the entire mesalamine concentration of the pill formulation is successfully administered to the colon, unlike a conventional mesalamine formulation, which would be partly depleted in the acidic environment of the stomach or mostly absorbed in the jejunum (the middle portion of the small intestine that connects the duodenum and the ileum, which are not part of the colon).


- Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape._x000D_
- Detailed information on Apriso including product description, safety and efficacy profiles as well as a SWOT analysis._x000D_
- Sales forecast for Apriso for the top six countries from 2012 to 2022._x000D_
- Sales information covered for the US, Germany, Spain, the UK, China and India.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return_x000D_
- Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis_x000D_
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential_x000D_
- Make more informed business decisions from insightful and in-depth analysis of Apriso performance _x000D_
- Obtain sales forecast for Apriso from 2012-2022 in the top six countries (the US, Germany, Spain, the UK, China and India)

To view the table of contents for this market research report please visit
Roger Campbell
United States
Ph: 888-789-6604